Investigating cardiac biomarkers during dialysis treatments
Intradialytic Kinetics of Cardiac Biomarkers During Hemodialysis and Hemodiafiltration
This study tests how different dialysis methods affect heart health by looking at specific heart markers in patients with severe kidney disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 24 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Aalborg University Hospital Academic / other |
| Locations | 1 site (Aalborg) |
| Trial ID | NCT06526702 on ClinicalTrials.gov |
What this trial studies
This randomized, crossover study examines how selected cardiac biomarkers behave during hemodialysis and hemodiafiltration in patients with end-stage renal disease. It involves 24 participants who will undergo both high-flux hemodialysis and post-dilution hemodiafiltration, with a wash-out period in between. The study will measure baseline concentrations, changes during treatment, and post-dialysis rebound effects of cardiac biomarkers like troponin and brain natriuretic peptide. The aim is to understand the effectiveness of different dialysis methods on cardiac health.
Who should consider this trial
Good fit: Ideal candidates are clinically stable adults aged 18 and older with end-stage renal disease on maintenance hemodialysis or peritoneal dialysis.
Not a fit: Patients who cannot understand or sign informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management of cardiac health in patients undergoing dialysis.
How similar studies have performed: While similar studies have explored cardiac biomarkers in dialysis, this specific approach comparing high-flux hemodialysis and hemodiafiltration is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age of 18 years or older. * Clinically stable patients with end-stage renal disease treated with maintenance hemodialysis or peritoneal dialysis. * Regarding patients treated with hemodialysis: Dialysis access with an arteriovenous fistula and able to maintain a blood flow rate \>300 mL. Exclusion Criteria: - Not able to understand or sign informed consent.
Where this trial is running
Aalborg
- Department of Nephrology, Aalborg University Hospital — Aalborg, Denmark (Recruiting)
Study contacts
- Study coordinator: Caroline H Liboriussen, MD
- Email: c.liboriussen@rn.dk
- Phone: +45 97663777
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.